News & Analysis on Clinical Trial Services & Contract Research And Development
By Melissa Fassbender
- Last updated on
Pharm-Olam’s board of directors has elected Robert Davie, PhD, as the company’s new chief executive officer.
Davie succeeds David Grange, who will remain a director and vice chairman of the company’s board, supporting its work in US government-funded research.
“This is a very exciting time as I join and take the helm of my new company, Pharm-Olam,” Davie said. “I am focused on continuing to develop the strengths Pharm-Olam is known for – particularly our ability as a midsized CRO to be more nimble and responsive to our clients’ needs.”
In his first 90 days, Davie said he will be assessing where the company plans to further invest resources to enhance its therapeutic areas, including infectious disease, oncology-hematology and allergy, “with our significant strengths in rare disease and orphan drugs running across all.”
Previously Davie worked at Covance and was most recently the vice president and general manager of the global clinical development.